Alto Neuroscience, Inc. (ANRO) Financial Statements
Free cash flow over the same period: -$68.8M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ANROAlto Neuroscience, Inc.Follow ANRO — free
—
Price chart with a free account
- Market cap
- 862.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Research & development | 47.0 | 45.6 | 64.9 | |
| Operating income | -68.6 | -66.4 | -88.3 | |
| Pre-tax income | -61.4 | -63.2 | -84.2 | |
| Income tax | 0.0 | 0.0 | — | |
| Net income | -61.4 | -63.2 | -84.2 | |
| Diluted EPS ($) | -2.50 | -2.19 | -1.97 | |
| Diluted shares (mn) | 24.6 | 28.9 | — |
USD millions · SEC XBRL
Alto Neuroscience, Inc. — questions
- What is Alto Neuroscience, Inc.'s net income?
- -$84.2M over the twelve months to 2026-06-30.
- What is Alto Neuroscience, Inc.'s free cash flow?
- -$68.8M over the twelve months to 2026-06-30.
- What are Alto Neuroscience, Inc.'s diluted earnings per share?
- $-1.97 over the twelve months to 2026-06-30.
Every figure on this page comes from Alto Neuroscience, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.